Antibe Therapeutics Inc (ATBPF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 09-2022 | 06-2022 | 03-2022 | 12-2021 | 09-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -9,079 | -4,386 | -20,145 | -15,841 | -11,714 |
| Depreciation Amortization | N/A | N/A | 79 | 157 | 123 |
| Income taxes - deferred | 199 | 204 | N/A | N/A | N/A |
| Accounts receivable | 673 | 644 | 229 | 877 | -100 |
| Other Working Capital | 369 | -45 | 1,996 | -8,920 | 205 |
| Other Operating Activity | 700 | -6 | 4,342 | 13,292 | 2,505 |
| Operating Cash Flow | $-7,138 | $-3,589 | $-13,499 | $-10,435 | $-8,982 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -21,537 | -9,115 | N/A | N/A | N/A |
| PPE Investments | N/A | N/A | -7 | -6 | N/A |
| Other Investing Activity | 12,488 | 0 | -16,124 | -187 | -188 |
| Investing Cash Flow | $-9,049 | $-9,115 | $-16,132 | $-194 | $-188 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | -2 | -2 | N/A |
| Debt Issued | N/A | N/A | N/A | N/A | -2 |
| Common Stock Issued | N/A | N/A | 102 | 102 | 102 |
| Other Financing Activity | -60 | -31 | -121 | -90 | -60 |
| Financing Cash Flow | $-60 | $-31 | $-21 | $10 | $41 |
| Beginning Cash Position | 26,669 | 27,257 | 57,420 | 57,111 | 57,175 |
| End Cash Position | 10,423 | 14,523 | 27,769 | 46,492 | 48,047 |
| Net Cash Flow | $-16,247 | $-12,735 | $-29,651 | $-10,619 | $-9,129 |
| Free Cash Flow | |||||
| Operating Cash Flow | -7,138 | -3,589 | -13,499 | -10,435 | -8,982 |
| Capital Expenditure | N/A | N/A | -7 | -6 | N/A |
| Free Cash Flow | -7,138 | -3,589 | -13,506 | -10,442 | -8,982 |